SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Short Interest Update

SAB Biotherapeutics, Inc. (NASDAQ:SABSW) saw a significant decrease in short interest during the month of October. As of October 15th, there was short interest totalling 5,200 shares, a decrease of 56.7% from the September 30th total of 12,000 shares. Based on an average daily trading volume, of 9,800 shares, the days-to-cover ratio is presently 0.5 days.

SAB Biotherapeutics Stock Performance

Shares of SABSW stock remained flat at $0.05 during trading hours on Friday. 12,095 shares of the stock traded hands, compared to its average volume of 19,374. The business’s fifty day moving average is $0.03 and its two-hundred day moving average is $0.04. SAB Biotherapeutics has a 52-week low of $0.01 and a 52-week high of $0.19.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.